SEC Form 4 · accession 0001270734-26-000004
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deepika Pakianathan
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 9:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jun 12, 2026 | A | 6,009 | $0.00 | A | 64,074 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $16.64 | Jun 12, 2026 | A | 13,398 | A | — | Jun 11, 2036 | Ordinary Shares | 13,398 | 13,398 | D |
Explanation of responses
- F1This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.